Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations (2016 - 2025)

Adma Biologics (ADMA) has disclosed Cash from Operations for 13 consecutive years, with 35639000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 29.03% year-over-year to 35639000.0, compared with a TTM value of 50396000.0 through Dec 2025, down 57.53%, and an annual FY2025 reading of 50396000.0, down 57.53% over the prior year.
  • Cash from Operations was 35639000.0 for Q4 2025 at Adma Biologics, up from 13293000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 50216000.0 in Q4 2024 and bottomed at 33465250.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 299550.0, with a median of 6719029.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 853.36% in 2024, then tumbled 787.06% in 2025.
  • Year by year, Cash from Operations stood at 33465250.0 in 2021, then soared by 77.95% to 7379058.0 in 2022, then soared by 338.47% to 17597000.0 in 2023, then surged by 185.37% to 50216000.0 in 2024, then fell by 29.03% to 35639000.0 in 2025.
  • Business Quant data shows Cash from Operations for ADMA at 35639000.0 in Q4 2025, 13293000.0 in Q3 2025, and 21139000.0 in Q2 2025.